Interacting Drugs |
Human papillomavirus bivalent (types 16, 18) recombinant vaccine vs Immunosuppressants |
Security Level |
|
Mechanism |
Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Exceptions: Cytarabine (Liposomal). |
Management |
Monitor therapy |
Human papillomavirus bivalent (types 16, 18) recombinant vaccine vs Immunosuppressants
Post Review about Human papillomavirus bivalent (types 16, 18) recombinant vaccine vs Immunosuppressants Click here to cancel reply.
Other Interactions of Human papillomavirus bivalent (types 16, 18) recombinant vaccine
Other Interactions of Immunosuppressants
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.